23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ROYALTY PHARMA PLC › 2023-2024

ROYALTY PHARMA PLC 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ROYALTY PHARMA PLC’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 17Reported items
  • 410Asset managers, any item
  • 7,337Fund votes
  • June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 17 items on ROYALTY PHARMA PLC’s Form 8-K, filed June 6, 2024: 17 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ROYALTY PHARMA PLC in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ROYALTY PHARMA PLC

These tallies are ROYALTY PHARMA PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ROYALTY PHARMA PLC — official shareholder meeting results, meeting held June 6, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Pablo Legorreta 469,574,04816,360,95791,560 --24,764,077 97%Passed (calculated)—
Elect Director: Henry Fernandez 467,493,60518,441,85091,110 --24,764,077 96%Passed (calculated)—
Elect Director: Bonnie Bassler, Ph.D. 480,331,7285,609,04085,797 --24,764,077 99%Passed (calculated)—
Elect Director: Errol De Souza, Ph.D. 468,014,05117,919,66692,848 --24,764,077 96%Passed (calculated)—
Elect Director: Catherine Engelbert 482,164,2793,725,318136,968 --24,764,077 99.2%Passed (calculated)—
Elect Director: David Hodgson 474,265,79911,668,94591,821 --24,764,077 98%Passed (calculated)—
Elect Director: Ted Love, M.D. 457,219,82728,488,315318,423 --24,764,077 94%Passed (calculated)—
Elect Director: Gregory Norden 472,819,63013,114,79492,141 --24,764,077 97%Passed (calculated)—
2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers 448,091,22537,716,521218,819 --24,764,077 92%Passed (calculated)—
3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm 510,538,774175,86676,002 ---- 99.9%Passed (calculated)—
4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditors' report for the fiscal year ended Dece 510,158,48964,644567,509 ---- 99.9%Passed (calculated)—
5. To approve, the Company's U.K. directors' remuneration policy, included in U.K. directors' remuneration report contained in the U.K. Annual Report and Accounts 446,941,63338,920,774164,158 --24,764,077 92%Passed (calculated)—
6. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts 448,684,30637,116,575225,684 --24,764,077 92%Passed (calculated)—
7. To re-appoint Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are pre 510,533,472190,24166,929 ---- 99.9%Passed (calculated)—
8. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor 485,875,260100,51150,794 --24,764,077 99.9%Passed (calculated)—
9. To authorize the Board of Directors to allot shares 474,984,22610,910,963131,376 --24,764,077 98%Passed (calculated)—
10. To authorize the Board of Directors to allot shares without rights of pre-emption 455,564,24930,278,595183,721 --24,764,077 94%Passed (calculated)—

Source: ROYALTY PHARMA PLC, Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.

How asset managers voted at the ROYALTY PHARMA PLC 2023-2024 meeting

410 asset managers disclosed a vote on at least one ROYALTY PHARMA PLC item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ROYALTY PHARMA PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Bonnie Bassler, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 8 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 480,331,728AGAINST: 5,609,040

Prior year: 99.4% for (June 22, 2023 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Bonnie Bassler , Ph.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Bonnie Bassler, Ph.D.”): 480,331,728 for, 5,609,040 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 121,435,773 for, 13,261 against, 45,346 abstained.

FOR
FOR: 121,435,773AGAINST: 13,261ABSTAIN: 45,346
Largest asset managers voting on “Election of Directors: Bonnie Bassler , Ph.D.” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Catherine Engelbert

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 482,164,279AGAINST: 3,725,318

Prior year: 87.2% for (June 22, 2023 meeting) ▲ 12.0 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Catherine Engelbert

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Catherine Engelbert”): 482,164,279 for, 3,725,318 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 121,015,178 for, 385,403 against, 93,799 abstained.

FOR
FOR: 121,015,178AGAINST: 385,403ABSTAIN: 93,799
Largest asset managers voting on “Election of Directors: Catherine Engelbert” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National561,708302,978 00Mixed
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: David Hodgson

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 474,265,799AGAINST: 11,668,945

Prior year: 97.5% for (June 22, 2023 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: David Hodgson

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: David Hodgson”): 474,265,799 for, 11,668,945 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 121,050,633 for, 398,401 against, 45,346 abstained.

FOR
FOR: 121,050,633AGAINST: 398,401ABSTAIN: 45,346
Largest asset managers voting on “Election of Directors: David Hodgson” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National561,708302,978 00Mixed
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Errol De Souza, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 7 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 468,014,051AGAINST: 17,919,666

Prior year: 92.4% for (June 22, 2023 meeting) ▲ 3.9 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Errol De Souza, Ph.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Errol De Souza, Ph.D.”): 468,014,051 for, 17,919,666 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 118,778,319 for, 2,670,715 against, 45,346 abstained.

FOR
FOR: 118,778,319AGAINST: 2,670,715ABSTAIN: 45,346
Largest asset managers voting on “Election of Directors: Errol De Souza, Ph.D.” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab01,773,729 00Against
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios950,00047,944 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal31,485391,821 00Mixed
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Gregory Norden

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 472,819,630AGAINST: 13,114,794

Prior year: 83.2% for (June 22, 2023 meeting) ▲ 14.1 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Gregory Norden

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Gregory Norden”): 472,819,630 for, 13,114,794 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 120,644,730 for, 804,304 against, 45,346 abstained.

FOR
FOR: 120,644,730AGAINST: 804,304ABSTAIN: 45,346
Largest asset managers voting on “Election of Directors: Gregory Norden” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National561,708302,978 00Mixed
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust0379,450 00Against
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Henry Fernandez

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 467,493,605AGAINST: 18,441,850

Prior year: 85.3% for (June 22, 2023 meeting) ▲ 10.9 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Henry Fernandez

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Henry Fernandez”): 467,493,605 for, 18,441,850 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 118,243,354 for, 3,205,680 against, 45,346 abstained.

FOR
FOR: 118,243,354AGAINST: 3,205,680ABSTAIN: 45,346
Largest asset managers voting on “ELECTION OF DIRECTORS: Henry Fernandez” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab01,773,729 00Against
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios950,00047,944 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National561,708302,978 00Mixed
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal31,485391,821 00Mixed
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Pablo Legorreta

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 469,574,048AGAINST: 16,360,957

Prior year: 98.1% for (June 22, 2023 meeting) ▼ 1.5 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Pablo Legorreta

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Pablo Legorreta”): 469,574,048 for, 16,360,957 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 121,388,771 for, 263 against, 45,346 abstained.

FOR
FOR: 121,388,771AGAINST: 263ABSTAIN: 45,346
Largest asset managers voting on “Election of Directors: Pablo Legorreta” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST695,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Ted Love, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 457,219,827AGAINST: 28,488,315

Prior year: 98.4% for (June 22, 2023 meeting) ▼ 4.2 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Ted Love , M.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Ted Love, M.D.”): 457,219,827 for, 28,488,315 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 119,317,839 for, 2,071,195 against, 45,346 abstained.

FOR
FOR: 119,317,839AGAINST: 2,071,195ABSTAIN: 45,346
Largest asset managers voting on “Election of Directors: Ted Love , M.D.” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,535,3225,737 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed01,098,573 00Against
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST695,5630 00For
Eaton Vance689,8700 00For
State Street0534,568 00Against
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

To authorize the Board of Directors to allot shares without rights of pre-emption

Calculated outcomeCAPITAL STRUCTUREPassed (calculated)

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 455,564,249AGAINST: 30,278,595
Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Authorize the Board to allot shares without rights of pre- emption (special resolution).

ROYALTY PHARMA PLC’s own tally for this item (“10. To authorize the Board of Directors to allot shares without rights of pre-emption”): 455,564,249 for, 30,278,595 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 119,525,855 for, 1,965,158 against.

FOR
FOR: 119,525,855AGAINST: 1,965,158
Largest asset managers voting on “Authorize the Board to allot shares without rights of pre- emption (special resolution).” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard36,727,8711,411,683 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 98 asset managers. All 98 are in the interactive database (link above).

Authorize the Board to allot shares.

No official matchCAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: votes by 98 asset managers

The 98 asset managers below reported 121,449,478 for, 41,535 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 121,449,478AGAINST: 41,535
Largest asset managers voting on “Authorize the Board to allot shares.” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 98 asset managers. All 98 are in the interactive database (link above).

To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 12 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 448,091,225AGAINST: 37,716,521

Prior year: 94.5% for (June 22, 2023 meeting) ▼ 2.3 pts

Details: description as filed, official tally, votes by 410 asset managers

Description as filed by funds: A non-binding advisory vote to approve executive compensation.

ROYALTY PHARMA PLC’s own tally for this item (“2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 448,091,225 for, 37,716,521 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 98 asset managers voting on “A non-binding advisory vote to approve executive compensation.” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam07,017,976 00Against
BlackRock5,728,0380 00For
JPMorgan04,785,936 00Against
Transamerica2,882,8128,007 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2531 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios950,00047,944 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National302,978561,708 00Mixed
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST695,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal31,485391,821 00Mixed
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Fund voting reports, all 98 managers: 107,471,883 for, 14,093,606 against, 18,537 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 338 asset managers voting on “A non-binding advisory vote to approve executive compensation.” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Morgan Stanley35,191,7830 00For
Fidelity31,225,4530 00For
BlackRock14,412,7653,847 00For
VIKING GLOBAL INVESTORS LP11,543,7200 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.10,816,9310 00For
Swedbank Robur Fonder AB08,383,000 00Against
State Street7,447,9900 00For
JPMorgan2316,967,823 00Against
GEODE CAPITAL MANAGEMENT, LLC6,552,2280 00For
BAILLIE GIFFORD & CO LTD4,199,3060 00For
BAILLIE GIFFORD OVERSEAS LTD3,592,71761,873 00For
Northern Trust2,751,6970 00For
John Hancock2,652,6890 00For
Amundi267,8601,920,425 00Mixed
GENERAL ATLANTIC, L.P.2,055,0390 00For
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM02,014,933 00Against
NEW SOUTH CAPITAL MANAGEMENT INC1,922,4470 00For
HOMESTEAD ADVISERS CORP1,892,5400 00For
GMT CAPITAL CORP01,884,988 00Against
Janus Henderson1,882,2890 00For
Charles Schwab1,841,7890 00For
London LGPS CIV Ltd1,820,1820 00For
Legal & General Investment Management Ltd01,804,585 00Against
SUVRETTA CAPITAL MANAGEMENT, LLC1,632,9470 00For
Man Group plc01,473,940 00Against

Institutional-manager reports, all 338 managers: 173,455,967 for, 35,447,038 against, 39,884 abstained, 2,027 not voted, 163 unknown. Showing the 25 largest; every one is in the interactive database (link above).

To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 9 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 448,684,306AGAINST: 37,116,575
Details: description as filed, official tally, votes by 188 asset managers

Description as filed by funds: Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containing the directors' remuneration policy) for the fiscal year ended December 31, 2023

ROYALTY PHARMA PLC’s own tally for this item (“6. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts”): 448,684,306 for, 37,116,575 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 96 asset managers voting on “Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containin” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam07,017,976 00Against
BlackRock5,728,0380 00For
JPMorgan04,785,936 00Against
Transamerica2,882,8128,007 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2531 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios950,00047,944 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National302,978561,708 00Mixed
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal31,485391,821 00Mixed
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Fund voting reports, all 96 managers: 107,894,808 for, 13,579,462 against, 16,248 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 94 asset managers voting on “Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containin” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
BAILLIE GIFFORD & CO LTD4,199,3060 00For
BAILLIE GIFFORD OVERSEAS LTD3,592,71761,873 00For
Northern Trust2,751,6970 00For
NEW SOUTH CAPITAL MANAGEMENT INC1,922,4470 00For
GMT CAPITAL CORP01,884,988 00Against
RAYMOND JAMES & ASSOCIATES0736,307 00Against
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.329,4990 00For
Portolan Capital Management, LLC287,1570 00For
TORRAY INVESTMENT PARTNERS LLC272,2990 00For
JPMorgan231232,678 00Against
EVERGREEN CAPITAL MANAGEMENT LLC229,9400 00For
Overbrook Management Corp0209,268 00Against
J. Goldman & Co LP178,3880 00For
Ensign Peak Advisors, Inc177,8670 00For
Baillie Gifford Investment Management (Europe) Ltd176,3200 00For
Treasurer of the State of North Carolina0175,879 00Against
Korea Investment CORP173,7480 00For
Corient Private Wealth LLC110,704205 00For
Kovitz Investment Group Partners, LLC102,383576 00For
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC92,4520 00For
EASTERN BANK56,8380 00For
ENVESTNET ASSET MANAGEMENT INC043,482 00Against
Aurora Investment Counsel00 39,8840Abstain
Ridgewood Investments LLC31,0900 00For
ROCKEFELLER FINANCIAL LLC19,9770 00For

Institutional-manager reports, all 94 managers: 14,813,423 for, 3,430,451 against, 39,884 abstained, 163 unknown. Showing the 25 largest; every one is in the interactive database (link above).

To approve, the Company's U.K. directors' remuneration policy, included in U.K. directors' remuneration report…

Calculated outcomeCOMPENSATIONCORPORATE GOVERNANCEPassed (calculated)

Combines 7 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 446,941,633AGAINST: 38,920,774
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: Approve our U.K. directors' remuneration policy.

ROYALTY PHARMA PLC’s own tally for this item (“5. To approve, the Company's U.K. directors' remuneration policy, included in U.K. directors' remuneration report contained in the U.K. Annual Report and Accounts”): 446,941,633 for, 38,920,774 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 106,225,028 for, 15,359,761 against, 18,537 abstained.

FOR
FOR: 106,225,028AGAINST: 15,359,761ABSTAIN: 18,537
Largest asset managers voting on “Approve our U.K. directors' remuneration policy.” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam07,017,976 00Against
BlackRock5,728,0380 00For
JPMorgan04,785,936 00Against
Transamerica2,882,8128,007 00For
Charles Schwab01,773,729 00Against
Brighthouse1,578,2531 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios950,00047,944 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National302,978561,708 00Mixed
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal31,485391,821 00Mixed
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 7 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 485,875,260AGAINST: 100,511
Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory auditor.

ROYALTY PHARMA PLC’s own tally for this item (“8. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor”): 485,875,260 for, 100,511 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 100 asset managers below reported 121,462,845 for, 12,998 against, 18,537 abstained.

FOR
FOR: 121,462,845AGAINST: 12,998ABSTAIN: 18,537
Largest asset managers voting on “Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory audit” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 100 asset managers. All 100 are in the interactive database (link above).

To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 8 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 510,538,774AGAINST: 175,866

Prior year: 100.0% for (June 22, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.

ROYALTY PHARMA PLC’s own tally for this item (“3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm”): 510,538,774 for, 175,866 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 100 asset managers below reported 121,612,986 for, 12,998 against, 18,537 abstained.

FOR
FOR: 121,612,986AGAINST: 12,998ABSTAIN: 18,537
Largest asset managers voting on “Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 100 asset managers. All 100 are in the interactive database (link above).

To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports…

Calculated outcomeOTHERPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 510,158,489AGAINST: 64,644
Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports for the fiscal year ended December 31, 2023.

ROYALTY PHARMA PLC’s own tally for this item (“4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditor”): 510,158,489 for, 64,644 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 121,624,906 for, 16,248 abstained.

FOR
FOR: 121,624,906ABSTAIN: 16,248
Largest asset managers voting on “Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports fo” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

To re-appoint Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor under the U.K. Companies Act…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 7 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 510,533,472AGAINST: 190,241
Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next general meeting at which the U.K. annual report and accounts are presented to shareholders.

ROYALTY PHARMA PLC’s own tally for this item (“7. To re-appoint Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the”): 510,533,472 for, 190,241 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 121,462,845 for, 12,998 against, 18,537 abstained.

FOR
FOR: 121,462,845AGAINST: 12,998ABSTAIN: 18,537
Largest asset managers voting on “Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next genera” at ROYALTY PHARMA PLC, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard38,139,5540 00For
Fidelity33,129,6350 00For
Morgan Stanley11,541,0590 00For
Putnam7,017,9760 00For
BlackRock5,728,0380 00For
JPMorgan4,785,9360 00For
Transamerica2,890,8190 00For
Charles Schwab1,773,7290 00For
Brighthouse1,578,2540 00For
Waddell & Reed1,098,5730 00For
Advisor Managed Portfolios997,9440 00For
TIAA949,8830 00For
First Trust927,2230 00For
Jackson National864,6860 00For
JANUS INVESTMENT FUND793,9440 00For
MUTUAL FUND SERIES TRUST755,5630 00For
Eaton Vance689,8700 00For
State Street534,5680 00For
HOMESTEAD FUNDS INC483,4840 00For
Victory Capital454,9190 00For
Aberdeen451,0650 00For
Principal423,3060 00For
AIG/SunAmerica403,3270 00For
RBB Fund Trust379,4500 00For
AB EQUITY INCOME FUND INC366,8690 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Largest ROYALTY PHARMA PLC shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 448,623,000 shares outstanding at the time of that meeting.

Fund voting reports: top ROYALTY PHARMA PLC shareholders by shares voted on “A non-binding advisory vote to approve executive compensation.”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 8.50%
2Fidelity 7.38%
3Morgan Stanley 2.57%
4Putnam 1.56%
5BlackRock 1.28%
6JPMorgan 1.07%
7Transamerica 0.64%
8Charles Schwab 0.40%
9Brighthouse 0.35%
10Waddell & Reed 0.24%
Institutional-manager reports: top ROYALTY PHARMA PLC shareholders by shares voted on “A non-binding advisory vote to approve executive compensation.”, 2023-2024
#Asset manager % of shares outstanding
1Morgan Stanley 7.84%
2Fidelity 6.96%
3BlackRock 3.21%
4VIKING GLOBAL INVESTORS LP 2.57%
5ADAGE CAPITAL PARTNERS GP, L.L.C. 2.41%
6Swedbank Robur Fonder AB 1.87%
7State Street 1.66%
8JPMorgan 1.55%
9GEODE CAPITAL MANAGEMENT, LLC 1.46%
10BAILLIE GIFFORD & CO LTD 0.94%

Reported ROYALTY PHARMA PLC holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ROYALTY PHARMA PLC holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Continuing US Investors Partnership145,106,931 32.34%Proxy statement (DEF 14A), proxy filed April 25, 2024
GISEV Trustees Limited43,651,170 9.73%Proxy statement (DEF 14A), proxy filed April 25, 2024
Morgan Stanley41,159,749 9.17%Proxy statement (DEF 14A), proxy filed April 25, 2024
FMR LLC31,583,926 7.04%Proxy statement (DEF 14A), proxy filed April 25, 2024
FMR (Fidelity)27,986,714 6.24%Form 13F, quarter ended March 31, 2024
BlackRock26,200,503 5.84%Form 13F, quarter ended March 31, 2024
Vanguard Group10,936,538 2.44%Form 13F, quarter ended March 31, 2024
M. Germano Giuliani10,322,592 2.30%Proxy statement (DEF 14A), proxy filed April 25, 2024
State Street9,100,148 2.03%Form 13F, quarter ended March 31, 2024
Geode Capital6,548,054 1.46%Form 13F, quarter ended March 31, 2024

Percentages above are of 448,623,000 shares outstanding, as reported by ROYALTY PHARMA PLC on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ROYALTY PHARMA PLC's shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 410 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 7,337 separate fund positions. Their filings are grouped here into 17 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — A non-binding advisory vote to approve executive compensation. — FOR was 92% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ROYALTY PHARMA PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ROYALTY PHARMA PLC’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ROYALTY PHARMA PLC proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ROYALTY PHARMA (RPRX) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/royalty-pharma-plc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.